Patent · US Expired

Crystal modification B of 8-cyano-1-cyclopropyl-7-(1S,6S-2, 8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

US6664268B1 · kind B1 · utility

4Cited by

1References

9Claims

0Family size

Assignee

BAYER HEALTHCARE LLC · DE

Inventors

Thomas Himmler · Odenthal, DE
Werner Hallenbach · Nordhorn, DE
Hubert Rast · Leverkusen, DE

Key dates

Filing date	May 23, 2001
Grant date	Dec 16, 2003
Priority date	—
Expiry date	May 23, 2021

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P31/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a defined crystal modification of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid of the formula (I), to processes for its preparation and to its use in pharmaceutical preparations. The crystal modification can be distinguished from other crystal modifications of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid of the formula (I) by its characteristic X-ray powder diffractogram and its differential thermodiagram (see description).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.